Overview

Tranexamic Acid in Knee Joint Surgery

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Total knee joint replacement surgery can lead to significant blood loss, which can affect recovery after surgery. Tranexamic acid (TXA) is a medication which stops the breakdown of blood clots and therefore prevents blood loss. The optimal use of TXA remains a point of debate. Growing interest in the topical application of TXA (directly into the surgical wound) has been suggested as an alternative way of administering TXA, and may demonstrate similar effectiveness as when it is given intravenously. Therefore, this multicentred, randomized controlled trial, aims to investigate the safety and effectiveness of both topical and intravenous administrations of TXA in total knee joint surgery. The investigators predict that both routes of administration will demonstrate similar results when compared to placebo.
Phase:
Phase 4
Details
Lead Sponsor:
Andrew G Hill
Andrew G Hill, MBChB, MD (Thesis), EdD, FACS, FRACS
Treatments:
Tranexamic Acid